Iclusig
Payments companies reported to CMS as associated with Iclusig. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Iclusig, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Iclusig
These are the largest totals companies reported as associated with Iclusig. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| James Mccloskey | Hackensack, NJ | Medical Oncology | $199,663.13 |
| Hakan Kaya | Spokane, WA | Medical Oncology | $80,054.12 |
| Moshe Levy | Dallas, TX | Medical Oncology | $71,987.90 |
| Suzanne Fanning | Greenville, SC | Hematology & Oncology | $60,906.16 |
| Patricia Kropf | Charlotte, NC | Hematology (Internal Medicine) | $46,875.27 |
| Vincent Herrin | Jackson, MS | Hematology (Internal Medicine) | $39,522.58 |
| Elias Jabbour | Houston, TX | Hematology & Oncology | $38,799.19 |
| Imadeddine Tabbara | Washington, DC | Hematology & Oncology | $37,658.22 |
| Jorge Cortes-Franco | Houston, TX | Hematology & Oncology | $36,536.44 |
| Nikesh Shah | Tampa, FL | Hematology & Oncology | $31,838.21 |
Prescribed Iclusig?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.